EFFECTS OF ACE-INHIBITORS ON OXIDATION OF HUMAN LOW-DENSITY-LIPOPROTEIN

被引:28
作者
GODFREY, EG
STEWART, J
DARGIE, HJ
REID, JL
DOMINICZAK, M
HAMILTON, CA
MCMURRAY, J
机构
[1] WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND
[2] WESTERN INFIRM & ASSOCIATED HOSP,DEPT BIOCHEM,GLASGOW G11 6NT,SCOTLAND
[3] WESTERN INFIRM & ASSOCIATED HOSP,DEPT CARDIOL,GLASGOW G11 6NT,SCOTLAND
关键词
CAPTOPRIL; QUINAPRIL; QUINAPRILAT; ACE INHIBITORS; THIOL; SULFHYDRYL GROUP; N-ACETYLCYSTEINE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; OXIDATION; OXIDIZED LOW DENSITY LIPOPROTEIN;
D O I
10.1111/j.1365-2125.1994.tb04240.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxidation of low density lipoprotein (LDL) may be instrumental in the development of atherosclerosis. We have examined the effect of the angiotensin converting enzyme (ACE) inhibitors captopril and quinaprilat and the -SH containing compound N-acetylcysteine on LDL oxidation. Oxidation of isolated human LDL was initiated with CuCl2. Conjugated diene formation (monitored spectrophotometrically at 234 nm) gave a measure of LDL oxidation. Captopril inhibited LDL oxidation but quinaprilat did not. The lag phase to the rapid increase in absorbance at 234 nm determined was 109 (65-157) min median and range for control samples and rose to 209 (168-305) min with captopril 10 mum, a ratio of 2.1:1 for drug to control (P = 0.01). N-acetylcysteine had a similar effect to captopril (drug to control lag time ratio 2.0:1, with NAC 10 mum), i.e. suggesting resistance to oxidation was due to the -SH group of both drugs. Captopril may have a potentially anti-atherosclerotic property not shared by other ACE inhibitors.
引用
收藏
页码:63 / 66
页数:4
相关论文
共 26 条
  • [1] EFFECTS OF CAPTOPRIL ON ATHEROSCLEROSIS IN CYNOMOLGUS MONKEYS
    ABERG, G
    FERRER, P
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 : S65 - S72
  • [2] HEMIN - A POSSIBLE PHYSIOLOGICAL MEDIATOR OF LOW-DENSITY-LIPOPROTEIN OXIDATION AND ENDOTHELIAL INJURY
    BALLA, G
    JACOB, HS
    EATON, JW
    BELCHER, JD
    VERCELLOTTI, GM
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (06): : 1700 - 1711
  • [3] THE ANTIOXIDANT BUTYLATED HYDROXYTOLUENE PROTECTS AGAINST ATHEROSCLEROSIS
    BJORKHEM, I
    HENRIKSSONFREYSCHUSS, A
    BREUER, O
    DICZFALUSY, U
    BERGLUND, L
    HENRIKSSON, P
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01): : 15 - 22
  • [5] TRANDOLAPRIL INHIBITS ATHEROSCLEROSIS IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT
    CHOBANIAN, AV
    HAUDENSCHILD, CC
    NICKERSON, C
    HOPE, S
    [J]. HYPERTENSION, 1992, 20 (04) : 473 - 477
  • [6] ANTIATHEROGENIC EFFECT OF CAPTOPRIL IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT
    CHOBANIAN, AV
    HAUDENSCHILD, CC
    NICKERSON, C
    DRAGO, R
    [J]. HYPERTENSION, 1990, 15 (03) : 327 - 331
  • [7] CAPTOPRIL - A FREE-RADICAL SCAVENGER
    CHOPRA, M
    SCOTT, N
    MCMURRAY, J
    MCLAY, J
    BRIDGES, A
    SMITH, WE
    BELCH, JJF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (03) : 396 - 399
  • [8] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [9] DAVIES SW, 1991, BRIT HEART J, V66, P78
  • [10] PHARMACOKINETICS OF CAPTOPRIL IN HEALTHY-SUBJECTS AND IN PATIENTS WITH CARDIOVASCULAR-DISEASES
    DUCHIN, KL
    MCKINSTRY, DN
    COHEN, AI
    MIGDALOF, BH
    [J]. CLINICAL PHARMACOKINETICS, 1988, 14 (04) : 241 - 259